MBI Portfolio Spotlight: Conigen Bioscience

At MBI, we are proud to support innovative startups  that are shaping the future of biotechnology through our unique StartUp and ScaleUp incubation models. One such MBI portfolio company is Conigen Bioscience, a cutting-edge startup in our portfolio that is making significant strides in the field of immunotherapy.

Created in 2023 as a female-founded startup company, Jean Qui, PhD and Shixia Wang, PhD’s company has seen rapid success moving through our incubator. The company started in one StartUp laboratory with two co-founders, grew quickly to about eight employees and expanded into more StartUp labs and then a larger ScaleUp laboratory, and now boasts over fifteen employees and has multiple laboratories to suit their needs in our pilot Biomanufacturing Center.

Conigen Bioscience is focused on developing advanced therapies to harness the power of the immune system in the fight against cancer and other diseases. By leveraging proprietary technologies and a deep understanding of immunology, Conigen is working to create targeted, effective treatments that improve patient outcomes

As part of the MBI community, the Conigen team benefits from our collaborative environment, state-of-the-art lab facilities, and robust network of mentors, investors, and industry leaders. Their progress exemplifies the potential of startups to go from Concept to Clinical Trials all under one roof. We are thrilled to support Conigen Bioscience and the rest of the MBI portfolio companies as they advance their mission to revolutionize healthcare!